G1 Therapeutics Inc. (GTHX)
NASDAQ: GTHX
· Real-Time Price · USD
7.16
0.01 (0.14%)
At close: Sep 17, 2024, 7:56 PM
0.14% (1D)
| Bid | 7.14 |
| Market Cap | 377.75M |
| Revenue (ttm) | 58.2M |
| Net Income (ttm) | -44.77M |
| EPS (ttm) | -0.86 |
| PE Ratio (ttm) | -8.325581395348838 |
| Forward PE | n/a |
| Analyst | Hold |
| Ask | 7.16 |
| Volume | 1,097,310 |
| Avg. Volume (20D) | 2,229,441 |
| Open | 7.15 |
| Previous Close | 7.15 |
| Day's Range | 7.14 - 7.16 |
| 52-Week Range | 1.08 - 7.19 |
| Beta | 1.68 |
About GTHX
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer...
Industry Biotechnology
Sector Healthcare
IPO Date May 17, 2017
Employees 100
Stock Exchange NASDAQ
Ticker Symbol GTHX
Website https://www.g1therapeutics.com
Analyst Forecast
According to 2 analyst ratings, the average rating for GTHX stock is "Hold." The 12-month stock price forecast is $3, which is a decrease of -58.10% from the latest price.
Stock Forecasts8 months ago
G1 Therapeutics shares are trading higher after th...
Unlock content with
Pro Subscription
10 months ago
G1 Therapeutics shares are trading lower after the company's PRESERVE 2 Phase 3 trial of Trilaciclib did not achieve statistical significance in the primary endpoint of overall survival.